PartnershipJun 4, 2026, 08:32 AM
Veru Partners with Novo Nordisk for Phase 2b Obesity Study
AI Summary
Veru Inc. announced a clinical supply agreement with Novo Nordisk A/S for its Phase 2b PLATEAU clinical study. The study will evaluate Veru's enobosarm in combination with Novo Nordisk's Wegovy for weight reduction in older adults with obesity. Veru will sponsor and conduct the study, while Novo Nordisk will supply Wegovy at no charge. Veru retains global rights to enobosarm but granted Novo Nordisk a right of first negotiation for future collaborations involving enobosarm with Novo Nordisk GLP-1 products.
Key Highlights
- Veru entered a clinical supply agreement with Novo Nordisk for its Phase 2b PLATEAU study.
- The study evaluates Veru's enobosarm combined with Novo Nordisk's Wegovy for obesity in older adults.
- Veru is solely responsible for sponsoring and conducting the Phase 2b PLATEAU study.
- Novo Nordisk will supply Wegovy to Veru at no charge for the clinical trial.
- Veru granted Novo Nordisk a right of first negotiation for future enobosarm/GLP-1 combinations.
- Veru retains full global development and commercialization rights to enobosarm.
Price Impact
More from VERU